hotspot -WSS

hotspot

author：fashion 2025-09-03 14:38:28 - browse：5

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Sweden knocks USA out of World Cup in penalty kicks

explore

WSS

World's first CRISPR

FDA's Woodcock to retire early next year

Many breast cancer patients receive more radiation than needed

Surge of respiratory disease in China has likely explanation

Sage considers ways to reduce costs following FDA rejection

NFL doctors' conflicts of interest could endanger players, report says

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

How CRISPR works, explained in two minutes

In Memoriam: Notable people who died in 2023

Gain of function research would be limited under House proposal

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Flash flood warnings continue for parts of Missouri, Illinois

Psychedelics group wrestles with new pharma identity

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Continuity nursing helped my family in our darkest PICU moments

Wegovy, Zepbound and weight loss drugs that preserve muscle

explore

Wegovy, Zepbound and weight loss drugs that preserve muscle

Childhood cancer progress stalls for Black, Hispanic kids: Report

Childhood cancer progress stalls for Black, Hispanic kids: Report

'Brian's Song' at 50 still offers lessons about cancer for today

Surge of respiratory disease in China has likely explanation

Childhood cancer progress stalls for Black, Hispanic kids: Report

hotspot

hotspot

explore

explore